|
Sotagliflozin Clinical Trials
6 actively recruiting trials across 4 locations
Also known as: INPEFA, SAR439954/LX4211
Pipeline
Phase 2: 1Phase 3: 3Phase 1/2: 1
Top Sponsors
- University of Pennsylvania1
- University of Dundee1
- University of California, San Diego1
- Steno Diabetes Center Copenhagen1
- Lexicon Pharmaceuticals1
Indications
- Heart Disease5
- Diabetes4
- Type 1 Diabetes3
- Heart Failure3
- Obstructive Cardiomyopathy, Hypertrophic1
Other2 trials
Phoenix, Arizona1 trial
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Investigational Site (4041)
Phase 3
La Jolla, California1 trial
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
UC San Diego Altman Clinical & Translational Research Institute
Phase 1/2
Stanford, California1 trial
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Stanford University Medical Center
Phase 3
Philadelphia, Pennsylvania1 trial
Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression
University of Pennsylvania
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.